Drug intelligence / Profile preview

let-7b-5p mimic

Development stage
Preclinical
Modality
Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous, Intravenous
01

Overview

let-7b-5p mimic is a synthetic double-stranded RNA oligonucleotide designed to mimic the activity of the endogenous tumor-suppressive microRNA let-7b-5p. It acts by binding to the 3'-untranslated regions (3'-UTRs) of target mRNAs, leading to translational repression or mRNA degradation. Key direct targets of let-7b-5p include cell cycle and oncogenic regulators such as CDK6, AURKB, HMGA2, IGF1, and IGF1R. Ectopic restoration of let-7b-5p using mimics has been widely investigated in preclinical research for its therapeutic potential in various cancers (including pancreatic, breast, and colon cancers) to overcome chemoresistance and inhibit tumor progression, as well as in cardiovascular conditions like aortic dissection and pulmonary embolism to suppress inflammation and pathological remodeling.

Other names
hsa-let-7b-5p agomirhsa-let7b-5p agomirhsa-let 7b-5p agomirhsa-let-7b-5p mimichsa-let7b-5p mimichsa-let 7b-5p mimiclet-7b-5p miRNA mimiclet7b-5p miRNA mimiclet 7b-5p miRNA mimicmiR-let-7b-5p mimicmiR-let7b-5p mimicmiR-let 7b-5p mimicmicroRNA let-7b-5p mimic
02

Targets

CDK6 (Cyclin-dependent kinase 6)HMGA2 (High mobility group AT-hook 2)IGF-1 (Insulin-like growth factor 1)IGF-1R (Insulin-like growth factor 1 receptor)SOCS1 (Suppressor of cytokine signaling 1)TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)AURKB (Aurora kinase B)

Beyond the preview

Go deeper on let-7b-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on let-7b-5p mimic.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call